Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed colorectal carcinoma
• * Metastatic disease
• Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as \> 20 mm by conventional techniques or \> 10 mm by spiral CT scan
• Brain metastases allowed provided they have been treated and stable for \> 4 weeks
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-2
• Life expectancy ≥ 12 weeks
• ANC ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• AST/ALT ≤ 3 times upper limit of normal (ULN)
• Total bilirubin ≤ 1.5 times ULN
• PT (INR) ≤ 1.5
• Creatinine \< 1.5 times ULN
• Creatinine clearance ≥ 30 mL/min
• Urine protein:creatinine ratio \< 1.0 OR \< 1 g protein by 24-hour urine collection
• Not on dialysis
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception before, during, and for 4 weeks after completion of study treatment
• Prior non-colonic malignancies allowed provided there is no current clinical evidence of persistent or recurrent disease AND the patient is not on active therapy, including hormonal therapy
• No uncontrolled hypertension, defined as systolic BP \> 150 mm Hg or diastolic BP \> 90 mm Hg, despite antihypertensive medications
• No cardiac disease, including any of the following:
• * NYHA class III-IV congestive heart failure
• * Unstable angina (anginal symptoms at rest)
• * New onset angina (began within the past 3 months)
• * Myocardial infarction within the past 6 months
• * Uncontrolled arrhythmia
• No thrombolic or embolic events (e.g., cerebrovascular accident including transient ischemic attacks) within the past 6 months
• No serious non-healing wound, ulcer, or bone fracture
• No significant traumatic injury within the past 28 days
• No neuropathy ≥ grade 2
• No evidence of bleeding diathesis or coagulopathy
• No condition that would impair the patient's ability to swallow whole pills
• No malabsorption problem
• No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
• No known G-6PD deficiency
• No retinal or visual field changes from prior 4-aminoquinoline compound use
• No history of allergic reactions attributed to compounds of similar chemical or biologic composition to capecitabine or hydroxychloroquine
• No other concurrent serious systemic disorders (including active infections) that, in the investigator's opinion, would compromise the safety of the patient or compromise the patient's ability to complete the study
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• No prior chemotherapy for metastatic disease, except for adjuvant therapy that was completed ≥ 6 months before the first evidence of metastasis
• More than 28 days since prior major surgical procedure or open biopsy
• No concurrent anticoagulation with warfarin
• * Concurrent low molecular weight heparin (or an equivalent drug) allowed
• No concurrent hydroxychloroquine for treatment or prophylaxis of malaria
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No concurrent St. John wort
• No other concurrent investigational or anticancer agents or therapies